- GenKey, an integrated turn-key solution for transitioning to fuel cell power
- ProGen, a fuel cell stack and engine technology used in mobility and stationary fuel cell systems, and as engines in electric delivery vans; liquefaction systems; and electrolyzers that are hydrogen generators optimized for clean hydrogen production
- GenCare, an ongoing Internet of Things-based maintenance and on-site service program for GenDrive and GenSure fuel cell systems, GenFuel hydrogen storage and dispensing products and ProGen fuel cell engines
The company sells its products through a direct product sales force, original equipment manufacturers and dealer networks.
Plug Power stock has a $24 target price at UBS. The consensus target is lower at $19.00. On Friday, shares traded at $9.30 apiece.
Teva Pharmaceutical
This leading generic drug maker is trading at 25-year lows and could be a steal at current prices. Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) develops, manufactures, markets and distributes generic medicines, specialty medicines and biopharmaceutical products in North America, Europe and elsewhere.
The company offers sterile products, hormones, high-potency drugs and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services, and it operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory and oncology areas.
The company’s products portfolio in the CNS field includes Copaxone for the treatment of relapsing forms of multiple sclerosis, Ajovy for the preventive treatment of migraine in adults and Austedo for the treatment of neurodegenerative and movement disorders associated with Huntington’s disease and tardive dyskinesia.
In the respiratory therapeutic area, products include ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, Braltus, Cinqair/Cinqaero, DuoResp Spiromax and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease.
Oncology therapeutic offerings consist of Bendeka, Treanda, Granix, Trisenox, Lonquex and Tevagrastim/Ratiograstim.
Teva has a collaboration with MedinCell for the development and commercialization of multiple long-acting injectable products and a risperidone suspension for the treatment of patients with schizophrenia.
The $14 Barclays target price is well above the $9.69 consensus target, and Teva Pharmaceutical Industries stock traded at $7.55 on Friday.
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with absolutely no track record or liquidity, and major Wall Street firms have research coverage.
Originally published at 24/7 Wall St.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
